No­var­tis stacks more pos­i­tive PhI­II da­ta on Cosen­tyx fran­chise — eye­ing ap­proval in non-ra­di­ograph­ic ax­i­al spondy­loarthri­tis

Days ago No­var­tis post­ed a brief note on pos­i­tive 16-week da­ta about Cosen­tyx’s ef­fects on non-ra­di­ograph­ic ax­i­al spondy­loarthri­tis, open­ing the door to an EMA sub­mis­sion in the in­di­ca­tion. Now the phar­ma gi­ant says it has the 52-week win need­ed to take to FDA reg­u­la­tors, too.

The new up­date puts No­var­tis’ block­buster IL-17A drug on par with Eli Lil­ly’s ri­val ther­a­py, Taltz, for which sim­i­lar re­sults were re­port­ed in April. Both drugs are al­ready ap­proved for an­oth­er type of spondy­loarthri­tis, but this par­tic­u­lar form of in­flam­ma­to­ry arthri­tis does not show vis­i­ble ev­i­dence of dam­age on X-rays.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.